Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
Trial Parameters
Brief Summary
This is a randomized open-label multicentre phase III superiority study of the effect of adding SABR to the standard of care treatment pembrolizumab on progression free survival in patients with oligometastases of a squamous cell carcinoma of the head and neck (SCCHN), histological confirmation of the primary disease at first diagnosis, and PD-L1 CPS ≥1. After eligibility check and signing informed consent, all patients will be prospectively enrolled in a 1:1 ratio between current standard of care treatment (pembrolizumab, Arm 1) vs. SABR + standard of care treatment (Arm 2) to oligometastases. Any radical treatment to the synchronous primary/ recurrent primary tumor and/or involved cervical nodes (surgery or radiotherapy), as decided by the local tumor board/ treating physicians, should be completed prior to enrolment.Surgical removal of metastases is allowed for diagnostic purposes or for brain metastases, as long as these metastases count toward the total number of 5 and at least one metastasis is left for treatment with SABR. Such surgical procedures should be performed prior to enrolment.
Eligibility Criteria
Main inclusion Criteria: * Male/female participants who are at least 18 years of age on the day of signing informed consent * Histologically confirmed HNSCC of the oral cavity, oropharynx, hypopharynx, larynx or cervical primary occult and histologically or radiologically confirmed oligometastatic disease. Histological characterization of one metastatic lesion is strongly recommended. * Patients with synchronous or metachronous oligometastatic disease according to the ESTRO/EORTC consensus (1-5 metastatic lesions, with or without primary/recurrent primary tumour and/or regional disease). * Amenable to first-line systemic treatment for R/M SCCHN. * For patients with oropharyngeal cancer: HPV status using p16 IHC evaluated locally. * PD-L1 CPS of at least 1 as evaluated locally. * Staging not older than 12 weeks before enrolment. * All the 1-5 metastases must be amenable to SABR. * Eligible for treatment with pembrolizumab. * Have measurable disease based on RECIST 1.1. * ECOG performanc